RHYTHM PHARMACEUTICALS INC RYTM
ASignal's systematic analysis rates RYTM as Neutral.
Reflects the latest available analysis · analyzed Nov 6, 2026
The case on RYTM
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (79.6% YoY)
- High gross margin (88.23%) indicating pricing power
- Positive free cash flow trend relative to peers in biotech
- MACD bullish crossover with expanding histogram
- Price above 20-day and 50-day moving averages
- Overbought RSI at 68.12 (approaching 70 threshold)
- Price trading above upper Bollinger Band, suggesting overextension
- Negative operating cash flow (-$81.79M)
- Negative profit and ROE (-69.03% net margin, -77.96% ROE)
- High valuation metrics: PB 82.76x, PS 25.93x, EV/Revenue 25.57x
- No Reddit retail interest (0 mentions)
See the full verdict on RYTM
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes RYTM
Most investors never get a second opinion, let alone several. ASignal runs RYTM past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.